Skip to main content
. 2020 Dec 3;10(12):2287. doi: 10.3390/ani10122287

Table 5.

Effect of dietary C. butyricum on serum immunity and antioxidant ability (mean ± SE 2).

Item Dietary Treatments 1 p-Value
CON AGP CBN CBH
Day 14
IgA 3, µg mL−1 75.46 ± 6.19 a 77.76 ± 6.73 a,b 90.16 ± 4.97 a,b 93.33 ± 5.88 b 0.047
IgM 3, mg mL−1 1.58 ± 0.17 a 2.01 ± 0.18 a 2.60 ± 0.13 b 1.93 ± 0.10 a 0.001
IgG 3, mg mL−1 5.24 ± 0.19 5.46 ± 0.18 5.70 ± 0.17 5.35 ± 0.23 0.142
IL-1β 3, pg mL−1 116.73 ± 5.28 103.11 ± 4.22 116.16 ± 2.21 108.74 ± 5.71 0.065
IL-2 3, pg mL−1 102.69 ± 2.05 100.14 ± 3.12 97.03 ± 3.09 97.83 ± 2.43 0.190
IL-6 3, pg mL−1 275.05 ± 5.74 267.11 ± 8.36 264.31 ± 6.33 273.59 ± 6.98 0.327
TNFα 3, pg mL−1 58.46 ± 1.74 a 53.10 ± 0.97 b 55.99 ± 1.13 a,b 54.78 ± 2.36 a,b 0.032
GSH-PX 3, U mL−1 582.48 ± 35.98 667.53 ± 30.20 674.93 ± 24.48 584.00 ± 31.07 0.066
OH 3 U mL−1 760.05 ± 32.09 a 609.66 ± 17.45 b 815.80 ± 36.27 a 632.87 ± 19.70 b <0.001
SOD 3 U mL−1 28.99 ± 3.82 28.42 ± 1.00 21.25 ± 3.90 28.43 ± 2.00 0.103
T-AOC 3 mMol L−1 0.75 ± 0.02 0.75 ± 0.04 0.74 ± 0.03 0.78 ± 0.01 0.714
H2O2 3 mMol L−1 45.19 ± 6.82 a,b 35.99 ± 1.38 a 41.45 ± 3.55 a,b 50.52 ± 2.04 b 0.019
NO 3 µmol mL−1 222.86 ± 22.68 206.19 ± 22.77 202.85 ± 5.26 173.33 ± 5.50 0.064
ALT 3 U L−1 54.56 ± 1.35 51.91 ± 0.92 51.77 ± 0.93 51.45 ± 1.52 0.112
AST 3 U L−1 25.92 ± 0.54 a,b 25.89 ± 1.32 a,b 21.89 ± 0.62 b 33.56 ± 1.44 a <0.001
ALP 3 U L−1 84.29 ± 0.80 a 62.65 ± 0.71 c 76.61 ± 2.39 b 63.44 ± 1.81 c <0.001
γ-GT 3 U L−1 31.60 ± 0.65 a 24.08 ± 0.63 b 20.56 ± 0.64 c 21.48 ± 0.82 c <0.001
CHE 3 U L−1 625.83 ± 10.43 a 554.48 ± 13.03 b 447.97 ± 13.21c 363.13 ± 16.45 d <0.001
Day 28
IgA, µg mL−1 92.34 ± 8.03 a 113.07 ± 8.65 b 125.82 ± 3.18 b 119.33 ± 5.45 b 0.012
IgM, mg mL−1 2.40 ± 0.15 a 2.77 ± 0.14 a,b 2.87 ± 0.10 b 2.67 ± 0.17 a,b 0.033
IgG, mg mL−1 6.01 ± 0.26 a 6.52 ± 0.23 a 7.44 ± 0.17 b 6.42 ± 0.13 a 0.001
IL-1β, pg mL−1 101.28 ± 4.05 a 80.58 ± 5.65 c 87.70 ± 3.16 b,c 97.47 ± 3.95 a,b 0.011
IL-2, pg mL−1 103.53 ± 3.02 a 110.89 ± 3.76 a,b 118.77 ± 3.79 b 111.46 ± 2.82 a,b 0.038
IL-6, pg mL−1 287.41 ± 5.81 a 224.87 ± 6.87 b 240.04 ± 5.04 b 246.91 ± 10.15 b <0.001
TNFα, pg mL−1 53.01 ± 1.99 49.11 ± 2.38 48.74 ± 1.76 52.68 ± 2.56 0.224
GSH-PX, U mL−1 580.23 ± 38.00 a 646.27 ± 23.30 a,b 683.44 ± 36.46 b 604.81 ± 17.05 a,b 0.027
OH U mL−1 603.18 ± 10.77 a 607.34 ± 24.54 a 661.34 ± 8.32 b 612.88 ± 18.44 a,b 0.034
SOD U mL−1 19.30 ± 2.34 26.17 ± 2.19 22.29 ± 1.76 23.43 ± 3.81 0.08
T-AOC mMol L−1 0.76 ± 0.02 a,b 0.72 ± 0.02 a 0.77 ± 0.01 a,b 0.79 ± 0.02 b 0.034
H2O2 mMol L−1 74.66 ± 6.50 64.67 ± 4.33 63.72 ± 3.92 66.11 ± 4.89 0.171
NO µmol mL−1 77.14 ± 7.94 a 124.28 ± 7.40 c 101.90 ± 5.60 b 97.62 ± 6.41 b 0.001
ALT 3 U L−1 74.12 ± 1.22 a 79.98 ± 2.43 b 75.97 ± 1.44 a,b 75.61 ± 1.90 a,b 0.033
AST 3 U L−1 33.14 ± 0.94 b 34.68 ± 1.44 b 29.35 ± 0.80 c 43.45 ± 1.55 a <0.001
ALP 3 U L−1 45.11 ± 1.68 44.93 ± 1.56 42.43 ± 1.58 43.97 ± 1.29 0.273
γ-GT 3 U L−1 28.12 ± 1.16 a 25.87 ± 1.21 a 26.61 ± 1.09 a 32.98 ± 1.19 b 0.002
CHE 3 U L−1 460.86 ± 12.31 a 756.90 ± 8.94 c 561.46 ± 14.27 b 741.74 ± 17.50 c <0.001

a–c Different superscripts within a row indicate a significant difference (p < 0.05). 1 Dietary treatments: CON = basal diet; AGP = basal diet supplemented with 0.075 g/kg chlortetracycline, 0.055 g/kg kitasamycin, and 0.01 g/kg virginiamycin; CBN = basal diet supplemented with 2.5 × 108 CFU/kg C. butyricum; CBH = basal diet supplemented with 2.5 × 109 CFU/kg C. butyricum. 2 SE: standard error of the mean. Each treatment group contains six replicates (n = 6), and each replicate includes one piglet. 3 IgA immunoglobulin A; IgM immunoglobulin M; IgG immunoglobulin G; IL-1β, interleukin 1β; IL-2, interleukin 2; IL-6, interleukin 6; TNF-α, tumor necrosis factor α; GSH-PX, glutathione peroxidase; OH, inhibiting ability of hydroxyl radical; SOD, superoxide dismutase; T-AOC, total antioxidant capacity; H2O2, hydrogen peroxide; NO, nitric oxide; ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; γ-GT, gamma-glutamyl transpeptidase; CHE, Cholinesterase.